Nov. 19, 2026 — RevealDx has announced the launch of two new products, ReViewer and ReViz, ahead of the 2026 Radiological Society of North America (RSNA) Annual Meeting.
ReViewer is a Diagnostic Quality image viewer optimized for the identification and quantification of lung nodules. ReViewer enables deployment of the RevealAI-LUNG product into any PACS system and optimizes Radiologist workflow.
The company also introduced ReViz, a quality assurance and practice management dashboard that allows healthcare providers to monitor and track AI performance.
“We are excited to deliver these software solutions, and are looking forward to demonstrating all of them at RSNA 2026.” said Chris Wood, CEO of RevealDx. “We have invested heavily to ensure our products fit seamlessly into the radiology and billing workflow. Our goal is to reduce reading time while simultaneously integrating billable AI products.”
The announcement follows RevealDx's recent announcement that its new lung cancer screening CADx product, RevealAI-Screen, will be made available at no charge to U.S. patients (pending FDA clearance). Earlier this year, RevealDx also announced FDA clearance for RevealAI-Lung for use with incidentally detected lung nodules. The company received Medical Device Regulation (MDR) certification in November 2025 and has since deployed its technology at several institutions across the U.S. and Europe.
RevealDx customers can continue to choose to use any 3rd party nodule detector and nodule management system.
New Products at RSNA 2026
To learn more about RevealDx and RevealAI-Screen, please visit https://reveal-dx.com/.

November 11, 2026 